Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.

PURPOSE: We have shown previously that tumor infiltration by FOXP3+ regulatory T cells (Treg) is associated with increased relapse and shorter survival of patients with both in situ and invasive breast cancer. Because estrogen regulates Treg numbers in mice and promotes the proliferation of human T...

書目詳細資料
Main Authors:	Generali, D, Bates, G, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Dogliotti, L, Banham, A, Harris, A, Bottini, A, Fox, S
格式:	Journal article
語言:	English
出版:	2009

相似書籍

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
由: Generali, D, et al.
出版: (2008)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
由: Fox, S, et al.
出版: (2006)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
由: Fox, S, et al.
出版: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
由: Fox, S, et al.
出版: (2011)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
由: Mele, T, et al.
出版: (2010)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
由: Mele, T, et al.
出版: (2010)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
由: Generali, D, et al.
出版: (2009)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
由: Generali, D, et al.
出版: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
由: Generali, D, et al.
出版: (2007)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
由: Generali, D, et al.
出版: (2006)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
由: Generali, D, et al.
出版: (2006)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
由: Allevi, G, et al.
出版: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
由: Allevi, G, et al.
出版: (2013)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
由: Generali, D, et al.
出版: (2006)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
由: Foroni, C, et al.
出版: (2009)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
由: Generali, D, et al.
出版: (2011)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
由: Generali, D, et al.
出版: (2008)

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
由: A Ianza, et al.
出版: (2020-06-01)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
由: Andreis, D, et al.
出版: (2016)

Effect of Letrozole Administration as a Selective Aromatase Inhibitor on Male Rat's Reproductive Performance
由: A Hmood Jassim, et al.
出版: (2022-02-01)

Synergistic activity of letrozole and sorafenib on breast cancer cells.
由: Bonelli, M, et al.
出版: (2010)

Estrogen/androgen balance in men with hyperestrogenism normalized by using letrozole of the aromatase inhibitor drug class
由: Z. Sh. Pavlova, et al.
出版: (2022-03-01)

Interaction of Zinc Chloride with an Aromatase Inhibitor (Letrozole) on Anxiety in Adult Male Rats
由: Sahar Charghan, et al.
出版: (2016-12-01)

#120 : Effect of Aromatase Inhibitor, Letrozole on Semen Parameters in Eugonadotropic Hypoandrogenic Men with Oligozoospermia
由: Israt Jahan
出版: (2023-12-01)

Effect of Aromatase Inhibitor Letrozole on the Placenta of Adult Albino Rats: A Histopathological, Immunohistochemical, and Biochemical Study
由: Mohamed Ali Alabiad, et al.
出版: (2024-01-01)

Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas.
由: Bates, G, et al.
出版: (2008)

Letrozole, an aromatase inhibitor, improves seminal parameters and hormonal profile in aged endangered Markhoz bucks
由: Ako Rezaei, et al.
出版: (2022-11-01)

The aromatase inhibitor letrozole enhances the effect of doxorubicin and docetaxel in an MCF7 cell line model
由: Mary O’Neill, et al.
出版: (2012-12-01)

Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581.
由: Banham, A, et al.
出版: (2009)

Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and Theoretical Studies on Gold Nanoparticles
由: Alaa Edris, et al.
出版: (2023-04-01)

The FOXP3 transcription factor as a regulatory T-cell marker
由: Banham, A
出版: (2008)

Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation
由: Michele De Luca, et al.
出版: (2022-12-01)

Effectiveness of the aromatase (P450 Arom) inhibitors Letrozole and Exemestane for masculinization of red tilapia (Oreochromis spp.)
由: John J Betancur López, et al.
出版: (2014-03-01)

High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
由: Carreras, J, et al.
出版: (2006)

Monoclonal antibodies raised to the human FOXP3 protein can be used effectively for detecting Foxp3(+) T cells in other mammalian species.
由: Banham, A, et al.
出版: (2009)

The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
由: Giatromanolaki, A, et al.
出版: (2008)

Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
由: Rayoo, M, et al.
出版: (2009)

FOXP3+ regulatory T cells as biomarkers in human malignancies.
由: Bignone, P, et al.
出版: (2008)

Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
由: Panagiotis A. Konstantinopoulos, et al.
出版: (2024-04-01)

FOXP1: a potential therapeutic target in cancer.
由: Koon, H, et al.
出版: (2007)